🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

105 results for “AbbVie Deutschland GmbH & Co. KG” Clear

  1. Lutikizumab, Placebo of Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial
  2. Placebo for Risankizumab Solution for Injection 90 mg/mL, Risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial
  3. Placebo for risankizumab 300mg/3.33ml solution for infusion, ABBV-066 / Risankizumab, Placebo for Risankizumab 90mg/mL Solution for injection in Pre-filled Syringe, Risankizumab, ABBV-066, Risankizumab

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease

    phase 3 small molecule active

    1 trial
  4. Placebo for risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial
  5. Prednisolon 1 mg JENAPHARM, Prednisolon 5 mg JENAPHARM, Prednisolone placebo-5mg, Prednisolon 20 mg JENAPHARM, Prednisolone placebo-10mg, Prednisolon 10 mg JENAPHARM, Upadacitinib placebo, Upadacitinib, Prednisolone placebo-20mg, Prednisolone placebo-1mg, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial
  6. Risankizumab, Placebo for Risankizumab Solution for injection in prefilled syringe, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial
  7. Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial
  8. Telisotuzumab Vedotin, DOCETAXEL

    AbbVie Deutschland GmbH & Co. KG

    c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial
  9. Timolol vehicle, Bimatoprost SR sham applicator, Timolol, Bimatoprost SR, Bimatoprost SR

    AbbVie Deutschland GmbH & Co. KG

    Ocular hypertension, Open-angle glaucoma

    phase 3 small molecule active

    1 trial
  10. Truxima 500 mg concentrate for solution for infusion, Cyclophosphamide Injection 500 mg., Epcoritamab (GEN3013), Vincristine Sulfate 1 mg/ml solution for injection, Doxorubicinhydrochlorid Bendalis 2 mg/ml Injektionslösung, Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, Prednisone Zentiva 5 mg compresse

    AbbVie Deutschland GmbH & Co. KG

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial
  11. Upadacitinib Placebo, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    non-segmental vitiligo

    phase 3 small molecule active

    1 trial
  12. Upadacitinib Placebo, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Alopecia Areata

    phase 3 small molecule active

    1 trial
  13. Upadacitinib, DUPILUMAB, Upadacitinib, Upadacitinib, Upadacitinib, Upadacitinib, DUPILUMAB

    AbbVie Deutschland GmbH & Co. KG

    Dermatitis atopic

    phase 3 small molecule active

    1 trial
  14. Upadacitinib, Placebo for upadacitinib tablet, Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial
  15. Upadacitinib, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 162 mg solution for injection in pre-filled pen., Upadacitinib, RoActemra 20 mg/mL concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial
  16. Venetoclax, AZACITIDINE, Venetoclax, azacitidine, Venetoclax, azacitidine

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia in First Remission

    phase 3 small molecule active

    1 trial
  17. Venetoclax, Venetoclax, Cytarabine 100 mg/ml Solution for Injection or Infusion, Matching Placebo for Venetoclax, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  18. Venetoclax, Venetoclax, Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg film-coated tablets, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial
  19. Venetoclax, Venetoclax, Matching Placebo for Venetoclax, Venetoclax, AZACITIDINE

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  20. Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use

    AbbVie Deutschland GmbH & Co. KG

    Higher-Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial
  21. risankizumab placebo, Risankizumab, ABBV-066 / Risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial
  22. -, Pred Forte 10 mg/ml colirio en suspensión

    AbbVie Deutschland GmbH & Co. KG

    platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.

    phase 2 small molecule active

    1 trial
  23. ABBV-066, Lutikizumab

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 2 small molecule active

    1 trial
  24. ABBV-066, Lutikizumab, ABBV-382, ABBV-066 / Risankizumab, ABBV-8736

    AbbVie Deutschland GmbH & Co. KG

    Moderate to Severe Crohn’s Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources